Novo Nordisk Clinical Trial Shows: Wegovy Injection Reduces BMI and Obesity Rates in Children

By: finance.sina.com.cn|11/16/2026 16:57:09

Key Points

  • Novo Nordisk released complete data from a late-stage clinical trial: Wegovy significantly reduces the body mass index (BMI) of obese children aged 6-12.{#quote_NVO}
  • Wegovy is currently approved for obese children aged 12 and older, but there are no approved medications for obese children under 12.
  • The pharmaceutical company stated that no safety risks related to children's growth and puberty development were observed during the trial.

On April 28, 2025, in Waterbury, Vermont, USA, a Wegovy injection pen.

Novo Nordisk (NVO) announced on Monday the complete results of a late-stage clinical trial, revealing that its blockbuster injection drug Wegovy can help obese children aged 6 to 12 lose weight, significantly lowering their BMI.

Assuming adherence to medication, by week 68 of the trial, the average BMI reduction in the Wegovy group was estimated to be 19.7 percentage points higher than that of the placebo group; the BMI of children on the medication decreased by 17.4%, while the BMI of children in the placebo group increased by 2.2%.

If all enrolled children (including those who discontinued the medication) are included in the statistics, by week 68, the average BMI reduction of Wegovy compared to placebo was 16.2 percentage points. A total of 167 children participated in this study, and all subjects adhered to lifestyle interventions: a low-calorie diet combined with increased physical activity.

This detailed data brings encouraging progress in the treatment of childhood obesity. Childhood obesity is a chronic disease that can lead to serious cardiovascular, metabolic, and psychosocial consequences, and treatment options for younger children have been extremely limited. Without intervention, childhood obesity can persist into adulthood, leading to earlier and more severe health complications.

Dr. Andrea Trajina, Chief Medical Officer of Novo Nordisk's obesity program, stated: "This younger patient population bears an extremely heavy burden of disease."

According to data from the World Obesity Federation, there are approximately 177 million obese children and adolescents aged 5-19 globally in 2025; this number is expected to rise to 228 million by 2040.

Wegovy is currently approved for obese children aged 12 and older, but there are currently no approved medications for those under 12. The latest trial data demonstrates that Wegovy is expected to fill this treatment gap, safely and effectively improving the severity of obesity in children as young as 6.

In this trial by Novo Nordisk, 85% of the enrolled children were classified as moderately to severely obese at baseline (corresponding to adult BMI ≥35 and ≥40); nearly half of the subjects had already developed at least one obesity-related complication, such as hypertension, high cholesterol, or sleep apnea.

Under the condition of adhering to the medication, after 68 weeks of the trial, over 40% of children receiving Wegovy treatment were no longer classified as obese. Novo Nordisk first disclosed these preliminary trial results in September of this year.

Trajina stated: "These children develop the disease at a very young age, and it can progress and worsen rapidly. We hope to help control this chronic disease while they are still young."

Novo Nordisk reported that the overall safety and tolerability of the pediatric subjects were consistent with the results of adult clinical trials; no safety concerns affecting children's growth and puberty development were found during the trial.

However, Trajina also admitted that this two-year study cannot confirm whether early intervention in obesity can fundamentally change the long-term trajectory of the disease, nor does it answer what treatment and maintenance plans should be adopted as children transition into adulthood.

She pointed out: "This area still remains an evidence gap and requires further research in the future.

-- Price

--
--
--

This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.

You may also like

iconiconiconiconiconiconiconiconicon
Customer Support:@weikecs
Business Cooperation:@weikecs
Quant Trading & MM:bd@weex.com
VIP Program:support@weex.com